<DOC>
	<DOCNO>NCT00866008</DOCNO>
	<brief_summary>Background : By limit number embryo transfer uterus single embryo , risk multiple gestation reduce . In order improve effectiveness single embryo transfer , ability select embryo high potential develop healthy child vital importance . While embryos rat high quality standardize morphological assessment associate high implantation pregnancy rate , still possible predict certainty embryo implant high potential develop healthy child . An increase body evidence indicate incidence chromosomal abnormality embryos extremely high good embryo morphology necessarily exclude abnormal chromosomal constitution . Since aneuploidy consider main cause embryonic wastage loss , phenomenon may primarily responsible relatively poor pregnancy rate report IVF . The introduction fluorescent in-situ hybridization ( FISH ) techniques preimplantation genetic diagnosis enable screen embryo chromosomal aneuploidy transfer . Preimplantation genetic screening ( PGS ) would special interest couple think high risk develop chromosomally abnormal embryo , aim improve chance ongoing pregnancy IVF . PGS apply clinically numerous IVF laboratory throughout world , high rate chromosomal abnormality report IVF derive embryo . However , recent meta-analysis show PGS yet significant impact IVF outcomes . This may partly explain fact aneuploidy observe stage originate first mitotic division early preimplantation development , result chromosomally mosaic embryo . If chromosomally mosaic embryo biopsied , cell may representative remain embryo . The investigator ' group recently complete first prospectively design , randomize trial , compare embryo aneuploidy rate follow two ovarian hyperstimulation regime group 111 IVF patient . Milder stimulation associate reduction number oocytes retrieve embryos generate . However , proportion chromosomally normal embryos significantly increase . These result show first time direct correlation ovarian stimulation protocol incidence chromosome abnormality embryo . The observation mild stimulation patient still result high oocyte yield concur high proportion abnormal embryo , underscore need development minimal stimulation approach . Primary Objective : To determine whether administration hCG late follicular phase , instead continue fix dose FSH , result homogeneous cohort grow follicle development competent oocyte , lead low aneuploidy rate result embryo . Study design : Prospectively randomize , clinical study 110 woman undergo IVF treatment Intervention : Randomization one two ovarian stimulation protocol : 1 . Conventional regimen daily dose 225 IU recombinant FSH GnRH agonist long protocol co-treatment 2 . Mild ovarian stimulation regimen use endogenous FSH production start treatment day 5 menstrual cycle 150 IU / recFSH GnRH antagonist co treatment start day 6 . As soon two follicle reach 12 mm , treatment continue 200 IU / rec hCG . In arm , oocyte pick , insemination embryo culture perform accord standard procedure . On day 3 , suitable embryo biopsied one two blastomere remove , depend number cell within embryo . FISH analysis perform 10 chromosome ( 1 , 7 , 13 , 15 , 16 , 18 , 21 , 22 , X Y ) . Only chromosomally normal embryo transfer cryopreserved . Embryos diagnose aneuploid mosaic investigate implantation developmental potential , transfer vitro implantation model . After extended culture period , implantation behaviour assess entire embryo reanalysed detect proportion chromosomally abnormal cell . The implantation behaviour correlate type abnormality chromosome ( ) involve . Primary outcome parameter : Ovarian response , assess number oocyte obtain proportion chromosomally abnormal embryo per patient . Secondary outcome parameter : Number oocytes retrieve , fertilization rate proportion morphologically high quality embryos day 3 . Serum estradiol , LH , progesterone , androgen hCG level cycle day 3 day hCG .</brief_summary>
	<brief_title>A Study Effects Novel Ovarian Stimulation Regimen Embryo Aneuploidy Rates In Vitro Fertilization ( IVF )</brief_title>
	<detailed_description />
	<mesh_term>Aneuploidy</mesh_term>
	<criteria>Female age â‰¤ 37 year BMI 1829 kg/m2 Regular cycle ( 2535 day ) Standard indication IVF No major uterine abnormality Written inform consent Indication IVF male factor total motile sperm count &lt; 20x106 ICSI andrological indication Known abnormal ( male female ) karyotype Oocyte donation One previous IVF treatment result embryo transfer History recurrent abortion Medical contra indication pregnancy IVF treatment Relevant systemic disease Active substance abuse</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>IVF</keyword>
	<keyword>In vitro implantation</keyword>
	<keyword>Preimplantation genetic screening</keyword>
	<keyword>Aneuploidy</keyword>
</DOC>